The independent source for health policy research, polling, and news.
561 - 580 of 686 Results
UnitedHealth, a health industry goliath, has its hand in doctorsâ offices, surgery centers, technology services and prescription drugs. It is the industry model, and CVS and Aetna, says one expert, are âwannabes.â
House Republicans want to repeal federal tax credits that have helped spur a boom in orphan drugs for rare diseases.
A flurry of federal and state probes have targeted insulin manufacturers and pharmacy benefit managers â middlemen in the prescription drug-pricing pipeline. Here, we connect the legal dots.
Over the past two years, a powerful federal prosecutor and several state attorneys general have launched investigations related to diabetes drugs.
Gov. Jerry Brown signed the measure, which takes effect next year and will require drug companies to publicly justify big price increases.
"If it gets signed by this governor, it's going to send shock waves throughout the country,â one legislator says. Pharma has spent $16.8 million lobbying against this bill and other drug laws in California.
The drug, sold under the name Mavyret, can cure all six genetic types of the liver disease in eight weeks at a cost of $26,400, well below other options.
Drug companies are in the midst of a glossy publicity campaign to stop attempts to control rising pharma costs. But the devil is in the details.
Congress has yet to take substantive action on this growing consumer concern, but a number of states are flexing their cost-control muscle.
Research published this week by JAMA Cardiology analyzed pharmacy claims data related to a new class of cholesterol-lowering drugs.
At a political rally in March, President Donald Trump said drug prices are âoutrageousâ and blamed campaign contributions. Drugmakers funneled nearly $280,000 to Congress the very next day.
Any momentum to address prescription drug costs has been lost amid rancorous debates over replacing Obamacare and stalled by roadblocks erected via lobbying and industry cash.
The companyâs drug spending prediction, far above other insurers in the individual market, has experts scratching their heads. Anthem cites market volatility.
Ěý
Following a KHN investigation, the Food and Drug Administration has moved to speed up approvals of âorphan drugsâ while closing a loophole that allowed drugmakers to skip pediatric testing.
In this Facebook Live, KHNâs Julie Appleby talks with Stephanie Stapleton and answers readersâ questions about the prescription drug pricing pipeline and the industry stakeholders who have a role in what you pay.
A genetically altered cancer drug, based on CAR T-cell therapies, could be a big success with leukemia patients but at a staggering cost.
In this episode of âWhat the Health?â Mary Agnes Carey of Kaiser Health News, Sarah Karlin-Smith of Politico, Margot Sanger-Katz of The New York Times and Julie Appleby of Kaiser Health News discuss the recent extension of cost-sharing subsidies for millions of low-income beneficiaries on the Affordable Care Actâs marketplaces and the state of play on Capitol Hill and in the states concerning initiatives to lower prescription drug costs.
Medicaid spent billions more in 2016 than the year before on decades-old prescription drugs, including many generics, a Kaiser Health News data analysis shows.
Hospital use of two popular heart medicines, nitroprusside and isoproterenol, dramatically dropped after the prices for both soared.
Three years ago, only about a quarter of the nationâs large employers were very confident they would have a health plan in 10 years. That number has now risen to 65 percent.
Š 2026 KFF